China Health Resource Inc. Signs Official Letter of Intent with Leading Pharmaceutical Enterprise

Share Article

Letter of Intent signifies an increased Angelica purchasing capacity and 2011 revenue for China Health Resource Inc.

News Image

Dahurian Angelica Root

“As we continue the development and additions of new uses for DAR, we remain focused on exploring opportunities that will ensure a successful and stable future for our company."

China Health Resource Inc. (OTCBB: CHRI), a leading Chinese pharmaceutical company specializing in producing, processing and commercializing Dahurian Angelica Root (DAR), today officially announced the company has signed a Letter of Intent with Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd, a reputable leading enterprise within the pharmaceutical industry in China.

China Health Resource Inc. is well known for its high-quality Angelica in the native market of Sichuan, encouraging many dealers and pharmaceutical enterprises, both local and abroad, to work closely with the company in a long-term agreement for the supply of Angelica. In addition, the company has received GAP certification for Angelica production and exclusive use of “Sichuan Angelica”, the geographical logo.

“As we continue the development and additions of new uses for DAR, we remain focused on exploring opportunities that will ensure a successful and stable future for our company,” stated Jiayin Wang, CEO, China Health Resource, Inc. “Signing this Letter of Intent with such a respectable company within the Chinese pharmaceutical industry further strengthens our promising outlook for a successful 2011.”

The Letter of Intent provides in pertinent part, that Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd purchase a quantity of Angelica exceeding 320,000 kilograms (approximately 352 tons), guaranteeing China Health Resource, Inc. more than 5.76 million yuan (approximately USD$870,000) income for 2011. The companies anticipate the signing of the final binding Sales Contract. Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd has more than 50 stores in China, and has established relationships with various dealers in the United States, Australia and several other countries.

Additional information about China Health Resource, Inc. and Sichuan Zhiyuan Aquarious Pharmacy Co., Ltd can be found by visiting

About CHRI
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Press Contact:
Rebecca Binny-Hallmark
China Health Resource Inc.
(323) 403-3829

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Hallmark
Visit website